Edgar Filing: KIRK RANDAL J - Form 4

Form 4	J											
October 09, 2018												
FORM 4	UNITED	STATES	SECU	RITIFS	AND FX	CHANGE	COMMISSION	T	PPROVAL			
Washington, D.C. 20549							N OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See Instruction Subject See Instruction See Instruction								Estimated burden hou response	urs per			
See Instruction 1(b).	l	()										
(Print or Type Respondence)	nses)											
1. Name and Address of Reporting Person <u>*</u> KIRK RANDAL J			2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			[ZIOP]									
				of Earliest T Day/Year) 2018	ransaction		X_ Director10% Owner Officer (give titleOther (specify below) below)					
Fil				4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting 					
RADFORD, VA	. 24141						Person		1 8			
(City) ((State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned			
	ansaction Date hth/Day/Year)	Execution any	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, Amount	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Report on	a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.					
	·				inforr requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)			
	Tab					sposed of, or convertible	Beneficially Owned securities)	1				

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	iorDerivative	Expiration Date	Underlying Securities	De

Edgar Filing: KIRK RANDAL J - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr.	 Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 		(Month/Day/Year)		(Instr. 3 and 4)		See (In	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Series 1 Preferred Stock	<u>(1)</u>	10/05/2018		J			130,849	(1)	(1)	Common Stock	<u>(1)</u>	

Reporting Owners

Reporting Owner Name / Address	Relationships					
Treforming Connectionate Connection	Director	10% Owner	Officer	Other		
KIRK RANDAL J C/O THIRD SECURITY, LLC 1881 GROVE AVENUE RADFORD, VA 24141	Х					
INTREXON CORP C/O LEGAL DEPARTMENT 20374 SENECA MEADOWS PARKWAY GERMANTOWN, MD 20876		Х				
Signatures						
/s/ Randal J. Kirk		10/09/2018				
**Signature of Reporting Person		Date				
/s/ Randal J. Kirk, CEO of Intrexon Corporation		10/09/2018				
<pre>**Signature of Reporting Person</pre>		Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation ("Intrexon"), entered into a definitive license agreement to replace all existing agreements between the companies. In partial consideration for the termination of the

definitive needs agreement to replace an existing agreements between the companies. In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018.

Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer

(2) owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.